4-amino-7-[(1S,2S,3R)-2,3-(isopropylidenedioxy)-4-(trityloxymethyl)-4-cyclopenten-1-yl]-5H-pyrrolo[3,2-b]pyrimidine | 925672-06-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 4-amino-7-[(1S,2S,3R)-2,3-(isopropylidenedioxy)-4-(trityloxymethyl)-4-cyclopenten-1-yl]-5H-pyrrolo[3,2-b]pyrimidine
• CAS: 925672-06-6
• 化学式: C₃₄H₃₂N₄O₃
• 分子量: 544.653
• InChiKey: SRCSGPVIHUPRBN-XGNZJKERSA-N

反应信息

• 作为反应物：
  描述：

  4-amino-7-[(1S,2S,3R)-2,3-(isopropylidenedioxy)-4-(trityloxymethyl)-4-cyclopenten-1-yl]-5H-pyrrolo[3,2-b]pyrimidine 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以63%的产率得到4-amino-7-[(1S,2S,3R)-2,3-dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5H-pyrrolo[3,2-b]pyrimidine
  参考文献：
  名称：

  Enantioselective synthesis and antiviral activity of purine and pyrimidine cyclopentenyl C-nucleosides

  摘要：

  The enantiomerically pure carbocyclic purine and pyrimidine C-nucleosides 1-4 were synthesized via the key intermediate, 2,3-(isopropylidenedioxy)-4-(trityloxymethyl) -4-cyclopenten-1-ol (5), which was prepared from D-ribose in eight steps. Synthesized compounds were evaluated as potential antiviral agents against HIV, SARSCoV, Punta Toro, West Nile, and Cowpox viruses. However, only 9-deazaneplanocin A (1) exhibited moderate anti-HIV activity. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.10.043
• 作为产物：
  描述：

  在 potassium carbonate 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 反应 9.0h， 生成 4-amino-7-[(1S,2S,3R)-2,3-(isopropylidenedioxy)-4-(trityloxymethyl)-4-cyclopenten-1-yl]-5H-pyrrolo[3,2-b]pyrimidine
  参考文献：
  名称：

  Enantioselective synthesis and antiviral activity of purine and pyrimidine cyclopentenyl C-nucleosides

  摘要：

  The enantiomerically pure carbocyclic purine and pyrimidine C-nucleosides 1-4 were synthesized via the key intermediate, 2,3-(isopropylidenedioxy)-4-(trityloxymethyl) -4-cyclopenten-1-ol (5), which was prepared from D-ribose in eight steps. Synthesized compounds were evaluated as potential antiviral agents against HIV, SARSCoV, Punta Toro, West Nile, and Cowpox viruses. However, only 9-deazaneplanocin A (1) exhibited moderate anti-HIV activity. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.10.043